Navigation Links
Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility
Date:8/26/2011

PALO ALTO, Calif., Aug. 26, 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced that it has entered into an agreement with Bank of America, N.A. to repurchase $250 million of its common stock under an accelerated share repurchase program.  Concurrently, the company amended its revolving credit facility with Bank of America, N.A. to increase its borrowing capacity from $225 million to $300 million.

Under the accelerated repurchase agreement, Varian will pay $250 million to Bank of America N.A. and receive approximately 3.8 million shares, or 85 percent of the shares to be repurchased based on the closing share price of the company's common stock on August 24, 2011.  The total number of shares ultimately repurchased under the agreement will be determined upon final settlement.  Varian will either receive additional shares of common stock or under certain circumstances be required to remit a settlement amount payable at Varian's option in cash or common stock, based generally on the volume weighted average share price of Varian's common stock during the next three to six months.

"Accelerated repurchase programs have been an ongoing element of our overall strategy for returning value to our investors," said Tim Guertin, president and CEO of Varian Medical Systems.  The program is expected to be accretive to earnings going forward but have minimal impact on fiscal year 2011.

These shares will be acquired under the remainder of a 12 million share repurchase authorization approved by the company's Board of Directors on February 11, 2011 with an expiration at the end of fiscal year 2012.  At the conclusion of the accelerated share repurchase program, the company expects that approximately 7.4 million shares will remain under the February 11, 2011 authorization, depending on the company's stock price during the accelerated repurchase program.  Shares purchased under the accelerated share repurchase program will be retired.

The repurchase will be financed primarily through borrowings from the company's amended revolving credit facility.

As of the end of the third quarter of fiscal year 2011, the company had 119.1 million fully diluted shares outstanding.  Since initiating share repurchases at the end of fiscal year 2001, the company has spent $2.3 billion to repurchase 52 million shares of common stock at an average price of $44.49 per share.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.

Forward-Looking Statements

Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning the company's earnings growth, future financial results and any statements using the terms "could," "believe," "expect," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of economic conditions, including the strength of any recovery from the global recession; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; changes in third-party reimbursement levels; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; currency exchange rates and tax rates; the effect of adverse publicity;; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

FOR INFORMATION CONTACT:
Spencer Sias (650) 424-5782
spencer.sias@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems Schedules Investor Meeting at ASTRO in Miami Beach, FL
2. Scientific Presentations at 2011 AAPM/COMP Meeting Highlight TrueBeam® and RapidArc® Radiotherapy Systems From Varian Medical Systems
3. Researchers Find RapidArc® Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
4. David J. Illingworth Appointed to Board of Directors for Varian Medical Systems
5. South Florida Radiation Oncology on the Forefront of Cancer Treatment with the TrueBeam™ Radiotherapy System from Varian Medical Systems
6. Varian Medical Systems to Offer CIVCO Medical Solutions Body Pro-Lok™ for SBRT
7. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011
8. Scottish Executive Awards Varian Medical Systems Major Contract to Supply Advanced Radiotherapy Equipment to Scotlands Five Cancer Centers
9. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
10. NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
11. OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... Sept. 1, 2017 Michael Penna , ... , highlights opportunities for growth in his response to ... Marlin Equity is seeking a buyer for eMDs. Penna,s ... 22-year-old healthcare solutions Value Added Reseller and national leader ... "As the healthcare market continues to ...
(Date:8/31/2017)... Aug. 31, 2017 PM360,s annual Innovations ... to the latest innovations happening across the industry. Established ... to focus on providing a comprehensive look at the ... covers the most innovative companies, startups, divisions, products, services, ... "Everyone in this industry wants to ...
(Date:8/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the Morgan ... New York . John Greisch , ... at 11:05 a.m. Eastern Time. The live ... recorded replay will be available one hour after the conclusion ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology:
(Date:9/24/2017)... ... September 24, 2017 , ... “Star of Bethlehem Study”: is a thought-provoking ... the creation of published author, Duane Engdahl, an investigator who had has a long ... Duane Engdahl’s new book is a thought-provoking essay an event so significant that it ...
(Date:9/23/2017)... ... ... “You Can't Win Them All”: the story of an entrepreneur and a family man ... the lives of young athletes. “You Can't Win Them All” is the creation ... a small town in Northern Ontario, Canada. He is an entrepreneur who manages ...
(Date:9/22/2017)... ... September 22, 2017 , ... Fenwick Agency of Plano, TX ... they serve as part of the nationally recognized ‘Agents of Change’ movement. The agency ... organizations and community leaders to seek out those who most need help. Their hope ...
(Date:9/22/2017)... ... 2017 , ... SABRE is pleased to announce the ... a graduate student from Sonora, California, who will begin her studies this fall ... in Miami, Florida, was selected from a pool of more than 50,000 applicants ...
(Date:9/22/2017)... ... September 22, 2017 , ... TopConsumerReviews.com recently awarded their highest ... helps promote pancreatic health and regulate blood sugar levels . , Preventing ... have negative side effects, and with the changes in today’s healthcare industry, not ...
Breaking Medicine News(10 mins):